Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Genetics

Pharmaceutical

Clinical Trials

Third Quarter 2025 Financial Results

More Like This

Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera